Legal & General Group Plc Makes New $1.75 Million Investment in Tarsus Pharmaceuticals, Inc. $TARS

Legal & General Group Plc acquired a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 27,743 shares of the company’s stock, valued at approximately $1,746,000. Legal & General Group Plc owned 0.06% of Tarsus Pharmaceuticals at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Tarsus Pharmaceuticals by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,143 shares of the company’s stock valued at $1,137,000 after purchasing an additional 1,217 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Tarsus Pharmaceuticals by 2.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,220 shares of the company’s stock valued at $3,659,000 after buying an additional 1,394 shares during the last quarter. Jane Street Group LLC increased its holdings in Tarsus Pharmaceuticals by 105.8% in the 1st quarter. Jane Street Group LLC now owns 10,456 shares of the company’s stock worth $537,000 after buying an additional 190,000 shares during the period. JPMorgan Chase & Co. raised its position in Tarsus Pharmaceuticals by 402.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 140,610 shares of the company’s stock worth $5,696,000 after buying an additional 112,637 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in Tarsus Pharmaceuticals by 12.3% during the 2nd quarter. Invesco Ltd. now owns 928,501 shares of the company’s stock valued at $37,614,000 after acquiring an additional 101,978 shares during the period. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals News Roundup

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Tarsus completed its acquisition of Alkeus, obtaining worldwide rights to gildeuretinol (ALK-001), an investigational once-daily oral treatment for Stargardt disease. The rare inherited eye disease has no FDA-approved therapy and may affect up to 86,000 people in the United States. Tarsus completes Alkeus acquisition
• Positive Sentiment: ALK-001 is being evaluated in the global NORTHSTAR Phase 3 trial and has received FDA Breakthrough Therapy, Orphan Drug, Fast Track and Rare Pediatric Disease designations. The regulatory designations and potential to address a significant unmet need strengthen Tarsus’ pipeline, although topline trial data are not expected until 2029. Alkeus acquisition adds Phase 3 program
• Positive Sentiment: Newly published TEASE-1 results showed that daily gildeuretinol significantly reduced the growth rate of retinal atrophic lesions versus an untreated group and was well tolerated, with no reported delays in dark adaptation or night blindness. TEASE-1 study results
• Neutral Sentiment: The acquisition expands Tarsus beyond its commercial XDEMVY business and supports management’s strategy of building a broader eye-care company. However, the transaction’s financial terms and the ultimate commercial value of ALK-001 were not detailed in the reports.
• Negative Sentiment: Insider Elizabeth Lin reported multiple sales totaling approximately $898,000 across September 1–2 under a pre-arranged Rule 10b5-1 trading plan. While such planned transactions may not reflect current management views, the sales add a modest cautionary signal for investors.

Insider Activity

In other news, insider Elizabeth Lin sold 1,590 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $80.00, for a total transaction of $127,200.00. Following the completion of the transaction, the insider directly owned 4,770 shares of the company’s stock, valued at $381,600. This trade represents a 25.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Katherine Goodrich sold 2,954 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $62.08, for a total value of $183,384.32. Following the sale, the director owned 2,233 shares in the company, valued at approximately $138,624.64. This trade represents a 56.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 51,428 shares of company stock valued at $3,350,810 in the last quarter. Insiders own 9.64% of the company’s stock.

Tarsus Pharmaceuticals Stock Performance

NASDAQ:TARS opened at $90.78 on Monday. The stock has a 50-day simple moving average of $66.01 and a 200-day simple moving average of $65.96. The stock has a market cap of $3.98 billion, a P/E ratio of -83.28 and a beta of 0.54. Tarsus Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $91.53. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.17 and a current ratio of 3.20.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.24). The firm had revenue of $173.91 million for the quarter, compared to analysts’ expectations of $169.65 million. Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%. As a group, analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -2.06 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $88.00 price target on shares of Tarsus Pharmaceuticals in a research note on Thursday, July 9th. Mizuho lowered their price target on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Friday, July 17th. Oppenheimer upped their price objective on shares of Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Finally, Jefferies Financial Group upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Friday. Three analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $90.50.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.